Your password has been changed successfully.
|Please click here to Login with the new Password.|
According to a study, a new drug lowers heart attack and death risk by effectively reducing LDL cholesterol.
Known as alirocumab, the drug is a human antibody cloned from immune cells.
The study included almost 19,000 patients, and found a 24-percent reduction in cardiovascular events, like heart attack, and a 29-percent mortality reduction for people at the highest cholesterol risk.
But the treatment has been in clinical trials for a few years, with a couple available on the market, like Amgen's Repatha, which costs $14,000 annually.
The study used a new brand of alirocumab, called Praluent, that is projected to cost between $2,000 and $3,000 annually.